Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas.

Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC.

Sarcoma. 2010;2010:143540. doi: 10.1155/2010/143540. Epub 2010 Apr 18.

2.

FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.

Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC.

Clin Cancer Res. 2009 Apr 15;15(8):2856-63. doi: 10.1158/1078-0432.CCR-08-2537. Epub 2009 Apr 7.

3.

Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.

Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC.

Clin Cancer Res. 2008 Feb 1;14(3):715-20. doi: 10.1158/1078-0432.CCR-07-1762.

4.

Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.

Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA.

J Nucl Med. 2008 Oct;49(10):1579-84. doi: 10.2967/jnumed.108.053694. Epub 2008 Sep 15.

5.

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.

Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J.

Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9.

PMID:
20617404
6.

18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.

Dutour A, Decouvelaere AV, Monteil J, Duclos ME, Roualdes O, Rousseau R, Marec-Bérard P.

J Nucl Med. 2009 Sep;50(9):1533-40. doi: 10.2967/jnumed.109.062356. Epub 2009 Aug 18.

7.

PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.

Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, Skaltsa K, Domènech B, Lomeña F, Pons F.

Q J Nucl Med Mol Imaging. 2012 Jun;56(3):291-8.

PMID:
22695339
8.

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S.

J Nucl Med. 2013 Nov;54(11):1862-8. doi: 10.2967/jnumed.112.119271. Epub 2013 Oct 3.

9.

(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.

van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM.

Ann Surg Oncol. 2014 Sep;21(9):2831-7. doi: 10.1245/s10434-014-3791-6. Epub 2014 May 21.

PMID:
24845729
10.

Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.

Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV.

J Nucl Med. 2010 Dec;51(12):1863-9. doi: 10.2967/jnumed.110.079566. Epub 2010 Nov 15.

11.

[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.

Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M.

Ann Surg. 2009 Dec;250(6):888-94.

PMID:
19953708
12.

Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.

Denecke T, Hundsdörfer P, Misch D, Steffen IG, Schönberger S, Furth C, Plotkin M, Ruf J, Hautzel H, Stöver B, Kluge R, Bierbach U, Otto S, Beck JF, Franzius C, Henze G, Amthauer H.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1842-53. doi: 10.1007/s00259-010-1484-3. Epub 2010 May 27.

PMID:
20505933
13.

Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.

Im HJ, Kim TS, Park SY, Min HS, Kim JH, Kang HG, Park SE, Kwon MM, Yoon JH, Park HJ, Kim SK, Park BK.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):39-49. doi: 10.1007/s00259-011-1936-4. Epub 2011 Sep 28.

PMID:
21953008
14.

18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.

Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC.

Clin Cancer Res. 2012 Apr 1;18(7):2024-31. doi: 10.1158/1078-0432.CCR-11-2139. Epub 2012 Feb 14.

15.

Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer.

García Vicente AM, Cruz Mora MÁ, León Martín AA, Muñoz Sánchez Mdel M, Relea Calatayud F, Van Gómez López O, Espinosa Aunión R, Gonzalez Ageitos A, Soriano Castrejón A.

Tumour Biol. 2014 Nov;35(11):11613-20. doi: 10.1007/s13277-014-2495-7. Epub 2014 Aug 20.

PMID:
25139100
16.

Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.

Qin Z, Tang Y, Wang H, Cai W, Fu H, Li J, Ma C.

J Pediatr Hematol Oncol. 2015 Jul;37(5):396-401. doi: 10.1097/MPH.0000000000000323.

PMID:
25749587
17.

PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study.

Tateishi U, Kawai A, Chuman H, Nakatani F, Beppu Y, Seki K, Miyake M, Terauchi T, Moriyama N, Kim EE.

Clin Nucl Med. 2011 Jul;36(7):526-32. doi: 10.1097/RLU.0b013e3182175856.

PMID:
21637052
18.

Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.

Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW.

BMC Cancer. 2011 Jun 24;11:266. doi: 10.1186/1471-2407-11-266.

19.

Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.

Dancheva Z, Bochev P, Chaushev B, Yordanova T, Klisarova A.

Nucl Med Rev Cent East Eur. 2016;19(1):22-7. doi: 10.5603/NMR.2016.0005.

20.

¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.

Kong CB, Byun BH, Lim I, Choi CW, Lim SM, Song WS, Cho WH, Jeon DG, Koh JS, Yoo JY, Lee SY.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):728-36. doi: 10.1007/s00259-013-2344-8. Epub 2013 Jan 30.

PMID:
23361860

Supplemental Content

Support Center